eli lilly phase 3 trial retatrutide THIS is not a small step forward. It's a leap. A new of just dropped from and Company… and the results are genuinely unlike anything we've Today, we shared new data

Some participants actually report improved energy after the adjustment period, likely because carrying less weight and having better metabolic health increases baseline vitality

Results develop over weeks to months and vary significantly based on individual gut ecology

PMID: 28642676

[2] [11] As of 2026, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains an experimental compound available only within authorised clinical trial settings

Compared to control, significant reductions in intracranial pressure were seen acutely at 2.5 h and 24 h, but also at 12 weeks [101]

G., Mantovani, G